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Abstract: Stroke is a major health problem worldwide and nationally: the second leading 
cause of death and dementia, the most common cause of epilepsy in the elderly, and a 
common cause of depression. Stroke is associated with an increased rate of morbidity, 
but it is also the leading cause of long-term morbidity and disability in industrialized 
countries. Thrombolysis by administering intravenous recombinant tissue plasminogen 
activator (IV-rtPA) is the only treatment method "in the therapeutic window" recognized 
in international protocols. The benefit-risk ratio should be evaluated on a case-by-case 
basis, with the neurologist's decision being individual and often difficult. 
The aim of our study was to analyze the outcome of this procedure in our hospital since 
2015. We performed a retrospective clinical study of 77 patients with acute ischemic 
stroke subjected to IV-rtPA. Most patients with ischemic stroke undergoing intravenous 
thrombolysis did not receive chronic antithrombotictherapy. In most cases (76%) there 
was a decrease in the NIHSS score at 24 hours after thrombolysis and especially after 7 
days (between 3 and 19 points), reflecting a reduction in poststroke disability in 
thrombolyzed patients. In the series of patients undergoing i.v. thrombolysis 5 deaths 
(10%) were recorded, the lowestrate of data/death ratereported in the literature (14-
18%). 
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Introduction 
Stroke is a bleak reality of the society we 
live in through its effects on the physical and 
mental status of the patient and his/her socio-
professional reintegration. It is a major health 
problem worldwide and nationally: the second 
leading cause of death and dementia, the most 
common cause of epilepsy in the elderly, and a 
common cause of depression. Stroke is 
associated with an increased rate of morbidity, 
but it is also the leading cause of long-term 
morbidity and disability in industrialized 
countries. 
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Thrombolysis by intravenous (IV) 
administration of recombinant tissue 
plasminogen activator (rtPA) is the only 
treatment method "in the therapeutic window" 
recognized in international protocols to which 
Romania adhered through the National 
Program of Intervention in acute ischemic 
stroke. Alteplaza is currently the only 
thrombolytic agent that has proven effective 
through in international clinical trials, with a 
real impact on dependence and disability or 
risk of death after stroke. At the same time, it 
is not a risk-free therapeutic method, the main 
risk being the hemorrhagic one, a major risk 
for elderly patients with elevated blood 
pressure, diabetes and severe stroke. The 
benefit-risk ratio should be evaluated on a 
case-by-case basis, with the neurologist's 
decision being individual and often difficult. 
Difficulty in dealing with each patient is not 
only due to medical particularities but also to 
collateral aspects such as: problems with 
obtaining informed consent in patients with 
speech disturbances or confusional syndrome, 
timely interaction with patient's family, 
difficulty in communicating essential 
information in clear and understandable terms 
to a moderately or poorly informed 
population under the pressure of the "time is 
brain" principle. The disability due to ischemic 
stroke in patients undergoing thrombolysis 
with IV-rtPA is reduced or absent 3 months 
after the acute ischemic event, a 30% reduction 
in this disability not being accompanied by a 
significant change in mortality [1]. 
 
 
Material and method 
We performed a retrospective clinical 
study of 77 patients with acute ischemic stroke 
subjected to thrombolysis with IV-rtPA based 
on eligibility criteria assessed by neurologists 
on 24-hour duty between June 2015 and May 
2017 at the Iasi “Prof.dr. N. Oblu” 
EmergencyHospital. The data were collected 
from the medical records, emergency medical 
records, andintensive care observation charts. 
The following parameters were assessed: 
vascular risk factors, prior 
cardio/cerebrovascular risk prevention 
therapy (antiplatelet, anticoagulant, statin), 
severity of neurological deficit assessed with 
the NIHSS scale at baseline and in dynamics, 
ASPECTS radiographic score at stroke 
onset,time from stroke onset to the initiation 
of thrombolytic therapy. 
Results 
The age of enrolled patients ranged from 28 
to 92 year. 
Age distribution of patients 
 
 
Gender distribution of patients subjected 
to thrombolysis revealed a female 
predominance. 
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Gender distribution 
 
Most patients subjected to thrombolytic 
therapy had one or more vascular risk factors. 
Only 5 patients had an ischemic stroke of 
undetermined etiology, explained by 
incomplete laboratory assessment due to the 
logistic problem (lack of thrombophilia tests, 
absence of transthoracic or transesophageal 
echocardiogram, impossibility of Holter ECG 
monitoring). 
Arterial hypertension was the main 
vascular risk factor in most patients, especially 
in the group at very high additional risk. Atrial 
fibrillation, chronic ischemic heart disease, 
dyslipidemias, diabetes mellitus and chronic 
alcohol abuse were also present in the panoply 
of vascular risk factors in patients undergoing 
thrombolysis. 
 
Vascular risk factors in the patients subjected 
to thrombolysis 
 
Most ischemic strokestreated by 
thrombolysis involved the carotid system 
territory mainly on the topography of the 
middle cerebral artery, and only 10% had a 
vertebrobasilarsystem location. 
Arterial territory 
 
The average NIHSS score was 15 points, 
reflecting asignificant percentage of cases with 
severe neurological deficits, most likely a 
consequence of the long time interval between 
stroke from to hospital presentation to the 
hospital, but also of the still long time from 
presentation to thrombolysis administration. 
In most cases (76%) a decrease of NIHSS score 
(between 3 and 19 points) was recorded at 24 
hours and especially 7 days after thrombolysis, 
which reflects a reduction in 
poststrokedisability in the thrombolyzed 
patients. 
 
Clinical assessment 
 
Imaging assessment. Native cerebral CT 
scan in emergency revealed a 10-point 
ASPECTS score in most patients subjected to 
thrombolysis (80%), only one fifth of patients 
having an ASPECTS score of 7-10 points. 
Evaluation of the remnant neurologic deficit 
after thrombolysis therapy was made, 
according to the protocol, at 3 months for 49 
patients who underwent neuromotor 
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rehabilitation using the modified Rankin scale 
(mRS) and the Barthel capacity scale.  Of these, 
the majority (34 cases) had low mRSscores and 
high Barthel index scores, signifying a reduced 
severity of the remnant neurologic deficit after 
stroke. These scores correlated with the 
decrease of NIHSS score during acute stroke. 
 
Assessment at 3 month 
 
 
ASPECTS score 
 
Time intervals needed for the clinical and 
laboratory assessment of the patients eligible 
for thrombolytic therapy were compared with 
those specified in the national protocol; and 
international guidelines. The shortest time 
intervals were recorded for receiving the 
results of the compulsory tests specified in the 
thrombolysis protocol and result of imaging 
assessment, and the interval from presentation 
to emergency department (ED) to the 
initiation of thrombolysis was generally longer 
than recommended. 
 
Laboratory efficacy 
 
To illustrate we present the results of 
Priority Action for Interventional Treatment 
of Patients with Acute Stroke in accordance 
with data in the Romanian registry of 
Interventional Treatment for acute Stroke. 
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Interval stroke 
onset- ED 
presentation 
Interval ED 
presentation – 
brain CT scan 
Interval ED 
presentation –
receiving 
laboratory test 
results 
Interval stroke 
onset –treatment 
administration 
Interval ED 
presentation- 
treatment 
administration 
2012-2014 75 30 53 150 75 
2014-2015 65 30 44 135 70 
2015-2016 86 34 50 165 79 
2016 (Jan- Aug) 99 31 51.5 175.4 78.7 
Recommendations in 
international 
guidelines 
 25 45  60 
 
Most of the patients undergoing 
intravenous thrombolytic therapy were not on 
chronic antithrombotic treatment for 
secondary prevention at home. 
 
Home treatment prior to thrombolysis 
 
 
Prior statin treatment 
 
As to the patients on pre-stroke statin 
therapy, in only 5 of the 13 patients therapy 
was targeted at lowering LDL-cholesterol. 
Patients not on pre-stroke statin therapy 
accounted for the majority of those with high 
onset NIHSS score (greater severity of 
neurological symptoms) and also tended to 
have lower e ASPECTS scores. 
In the series of patients subjected to 
intravenous thrombolysis 5 deaths (10%) were 
recorded, rate lower than that reported in the 
literature (14-18%). 
 
Mortality rate 
 
Discussions 
Ischemic stroke is produced by 
thromboembolic or hemodynamic 
mechanism. The pathogenesis of cerebral 
infarction is complex and consists of several 
stages, the processes involved in cellular injury 
determining an ischemic cascade. A multitude 
of factors are considered in cell dysfunction 
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and death. Seconds to minutes after the loss of 
glucose and oxygen supply to neurons, the 
ischemic cascade begins. This is a complex 
process that starts with the discontinuation of 
the normal electrophysiological function of 
neurons. 
Pathophysiologically, the decrease in 
oxygen and glucose supply leads to 
inappropriate energy supply and thus 
tofailureofenergy dependent processes such 
asion pumping. The result is the disruption of 
ionic homeostasis, with the influx of Ca and 
water into the cells and lactic acidosis. Finally 
cytotoxic edema occurs. The role of excitatory 
amino acids (especially glutamate liberated 
from ischemic cells) is a key element because 
they bind to NMDA receptors and excite 
neurons, causing an influx of Ca and Na that 
activates the enzymatic cascade ultimately 
leading to irreversible cellular lesions and 
neuronal death. 
Other events induced by ischemia consist 
in free radical production, which causes lipid 
peroxidation and cell membrane rupture. 
Lactic acid accumulation and the consecutive 
biochemical changes are important in 
determining the extent of cellular lesions. 
In terms of anatomopathological lesions, 
focal cerebral ischemia has two areas: 
-1.”Core ischemic zone" at the center of the 
ischemic area where, through the depletion of 
energy reserves (blood flow <12 ml /100 mg 
/tissue /min), neuronal death (necrosis) 
occurs. 
-2. “Ischemic penumbra”, present both at 
the margin of ischemic focus and even within 
the cerebral infarction for a short period of 
time contains functionally altered but still 
viable cerebral tissue supplied with blood  by 
arteries - the "luxury perfusion" - (BF = 12-
23ml/100mg /tissue/min) [2]. At this level 
there is a risk of apoptotic-like cell death. IV-
rtPA thrombolysis diminishes the extent of the 
infarct area towards the penumbralzone and 
also causes an increase of reperfusion 
processes, as shown by the studies (EPITHET 
- Echoplanar Imaging Thrombolytic 
Evaluation Trial) [3]. 
Ischemic penumbra: 
-has a limited duration but may persist for 
over 12 hours after the occurrence of 
focalization signs due to ischemic stroke 
-may progress to infarction due to neural 
lesions secondary to some biochemical 
cascades with cytotoxic and excitotoxic effects 
-ion homeostasis and transmembrane 
potentials are maintained 
-being a dynamic process, it has potential 
for reversibility if and reperfusion and 
neuroprotection therapies are initiated as early 
as possible. 
The onset and time course of molecular 
processes are different. At the level of ischemic 
focus outbreak, increased excitotoxicity and 
secondary biochemical reactions cause 
necrosis in minutes to hours (within the first 
24h), while at the level of ischemic peninsula 
excitoxicity and secondary biochemical 
reactions cause apoptotic-like cell death which 
can last hours to days. 
Thus, the earlier the initiation of the 
therapeutic strategy aimed at restoring blood 
flow and providing neuroprotection, the 
higher the percentage of saved penumbral 
zone with potential for reversibility. Imaging 
assessment by perfusion CT scans and 
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magnetic resonance imaging (MRI) and 
determination of diffusion–perfusion 
mismatch would allow a correct selection of 
patients who may benefit most from 
thrombolysis due to accurate quantification of 
the infarct zone versus potentially reversible 
ischemic penumbra. The use of these brain 
imaging techniques also allowed the expansion 
of the therapeutic window for i.v. 
thrombolysis from 3 to 4.5 hours [4, 5] 
Revascularization therapy in acute 
ischemic stroke includes intravenous 
thrombolysis and endovascular treatment 
procedures (mechanical thrombectomy, intra-
arterial thromboaspiration, intra-arterial 
pharmacological thrombolysis, combined 
pharmacological and mechanical treatment). 
Patients with acute ischemic stroke within the 
first 4.5 hours of the onset of neurological 
deficits may be eligible for systemic 
thrombolysis with rtPA administered 
intravenously, the recommended dose in the 
protocol being 0.9 mg/kg body weight, up to a 
maximum dose of 90 mg, of which 10% is 
administered bolus and the remainder is 
perfused over 1 hour [6]. 
The narrow therapeutic window, reduced 
efficacy for large artery occlusion, 
contraindications to this treatment in patients 
who associate a higher risk for bleeding 
complications are elements limiting this type 
of therapy. The main and most feared post-
thrombolysis complication is intracerebral 
hemorrhage. It can be of varying degrees of 
severity, ranging from simple non-
systematized petechiae to well-defined 
hematomas with mass effect, and which may 
be asymptomatic or symptomatic, by clinical 
deterioration of more than 4 points on the 
NIHSS (National Institute of Health Stroke 
Scale). This major complication may occur 
early or late, more than 24 hours after 
thrombolytic therapy, and predictive factors 
are not clearly established. The increased risk 
of hemorrhage appears to be related to: 
advanced age, hypertension, diabetes, amyloid 
angiopathy, leukoaraiosis, severity of signs of 
early ischemia on CT scan, or cerebral 
ischemia volume evidenced by diffusion 
weighted MRI. According to some studies, the 
favorable post-thrombolysis course seems to 
correlate both with arterial rechanneling and 
with efficient collateral circulation [7,8, 9,10]. 
Although the therapeutic window for the 
rtPA treatment was extended to 4.5 hours, 
studies show that patients in whom 
thrombolysis was performed within the first 3 
hours show a double benefit compared to 
those in whom this therapeutic intervention is 
performed within 3- 4.5 hours [11]. That is 
why it is imperative that all lines of care, 
emergency services and all involved factors to 
be maximally effective, so that patients with 
acute ischemic stroke to have rapid access to 
clinical and laboratory assessments in order to 
be eligible thrombolytic therapy. And this 
means functional collaboration protocols 
between emergency medical services, 
ambulance service dispatching system, 
emergency department medical staff, 
neurologists and neuroradiology unit. 
Increasing the number of hospitals with stroke 
and thrombolysis units as well as lines 
dedicated 24/24 to thrombolysis could lead to 
an increase in the proportion of patients with 
thrombolyzed acute ischemic stroke of all 
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stroke cases [12]. Other elements to be 
considered in order to extend the application 
and increase the benefit of thrombolytic 
therapy could be: increased number of stroke 
units, access to modern vascular imaging 
techniques, and extension of interventional 
neuroradiology services. 
Another important aspect related to 
thrombolytic therapy in acute ischemic stroke 
is informed consent. Thrombolysis cannot be 
initiated without the patient's consent, which 
in many cases cannot be obtained because of 
language or understanding problems caused 
by stroke. Obtaining the consent from the 
patient's relatives may also be difficult, either 
because they are not present in due time in the 
hospital unit, or because the information given 
to them about the benefits vs. risk of 
thrombolysis is not sufficiently understood. 
Using and disseminating information 
materials about thrombolysis among the 
population or through media could shorten 
the time needed to obtain informed consent in 
order to save time until the actual initiation of 
thrombolytic therapy [13, 14, 15]. 
In conclusion the decision to initiate 
intravenous thrombolysis therapy in acute 
ischemic stroke during the therapeutic 
window remains an individualized and 
difficult one for the neurologist, because even 
when observing the indications in the national 
protocol, a number of decision-making 
elements remain incompletely clarified: 
- thrombolytic therapy in patients with 
neurological symptoms occurring in the 
morning on waking or in elderly patients; 
- use of the best neuroimaging method for 
assessing eligibility for thrombolysis and 
optimal benefit-risk assessment, 
- the optimal organization model of 
structures and services involved in acute 
stroke management, so as to provide the fastest 
circuits in view of providing access to 
thrombolytic therapy for as many patients as 
possible. 
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